Ganitumab is a human monoclonal antibody against type 1 insulin-like growth factor receptor ( IGF1R), designed for the treatment of cancers. Ganitumab was developed by Amgen. A phase III clinical trial (for metastatic pancreatic cancer) was abandoned in August 2012.

References

Amgen Abandoned drugs {{antineoplastic-drug-stub